SGMO | Sangamo Therapeutics
Category: Biotechnology company
Quick infos Headquarters: Richmond, California, United States Trade prices Volume: Market Cap: 633.59M Prev closed: Open: 6.01 High: 6.07 Low: 5.75 52 week low: 5.1 52 week high: 13.93 Dividends: No Dividends Next ER: May 5, 2022
About the Company Sangamo Therapeutics, Inc. is an American biotechnology company based in Richmond, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
Earnings History Date EPS / Forecast Revenue / Forecast August 10, 2022 May 5, 2022 -0.3 / -0.311128.23M / 27.29MBeat! February 24, 2022 -0.26 / -0.345528M / 26.82MBeat! November 4, 2021 -0.33 / -0.336928.56M / 25.96MBeat! August 5, 2021 -0.33 / -0.313127.87M / 26.53MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Jun 1, 2022 3.55 3.67 3.69
3.50
1.24M -2.74% May 31, 2022 3.65 3.69 3.72
3.58
1.69M -0.82% May 27, 2022 3.68 3.54 3.71
3.44
1.74M 3.95% May 26, 2022 3.54 3.41 3.63
3.41
1.61M 3.51% May 25, 2022 3.42 3.55 3.64
3.38
1.93M -3.66% May 24, 2022 3.55 3.96 3.99
3.51
2.29M -11.47% May 23, 2022 4.01 4.19 4.23
3.99
1.65M -3.14% May 20, 2022 4.14 4.07 4.18
3.98
3.97M 3.50% May 19, 2022 4.00 3.77 4.06
3.77
2.05M 6.10% May 18, 2022 3.77 3.90 3.97
3.68
1.90M -4.56% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company ISIN: US8006771062 CUSIP: 800677106 Founded:1995 Employees:131 News
Why Did Sangamo Stock Jump 20% Today? finance.yahoo.com Jun 2, 2022 5:20 pm
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast finance.yahoo.com Jun 2, 2022 4:15 pm
Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results finance.yahoo.com Jun 2, 2022 4:01 pm
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results finance.yahoo.com Jun 2, 2022 4:01 pm
Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial finance.yahoo.com Jun 2, 2022 6:52 am Sangamo Therapeutics stock slips despite Q1 revenue beat seekingalpha.com May 6, 2022 11:02 pm Sangamo Therapeutics GAAP EPS of -$0.30 beats by $0.01, revenue of $28.23M beats by $0.94M seekingalpha.com May 6, 2022 4:06 am
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com May 5, 2022 5:45 pm Sangamo Therapeutics Q1 2022 Earnings Preview seekingalpha.com May 5, 2022 5:35 am
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com May 4, 2022 6:35 pm
What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Registry? finance.yahoo.com Apr 11, 2022 8:59 am
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation finance.yahoo.com Mar 29, 2022 8:05 am
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results finance.yahoo.com Mar 24, 2022 4:01 pm
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights finance.yahoo.com Mar 24, 2022 4:01 pm
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates finance.yahoo.com Mar 24, 2022 10:25 am Sangamo Therapeutics rises 5% after hours following Q4 earnings seekingalpha.com Feb 25, 2022 7:03 am Sangamo Therapeutics GAAP EPS of -$0.26 beats by $0.09, revenue of $28M beats by $0.64M seekingalpha.com Feb 25, 2022 5:02 am
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates finance.yahoo.com Feb 24, 2022 6:20 pm Sangamo Therapeutics Q4 2021 Earnings Preview seekingalpha.com Feb 24, 2022 6:35 am
PrairieView Partners, LLC Buys iShares Short-Term National Muni Bond ETF, Avantis Core ... finance.yahoo.com Jan 21, 2022 5:38 pm This company doesn't provide a dividend.
Key Persons CEO : Alexander Macrae, PhD Talk about Sangamo Therapeutics below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Homepage: sangamo.com Consensus BUY 60 HOLD 40 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.